CASE STUDIES
Overcoming Sourcing Challenges for a High-Demand Drug with a Smart Combination of Sourcing Pathways
Study: A Phase II US weight-loss clinical trial
Participants: 200 patients
Solution: Combining capabilities for commericial drug sourcing
Challenge
Sourcing the commercial drug for this dose-escalation weight-loss clinical trial proved to be a critical challenge. The sponsor anticipated long lead times and potential delays, particularly for certain dosages under high pressure. This scarcity stemmed from the drug’s overwhelming demand on the market at the time.
Ensuring timely and reliable supply of all required dosages was pivotal to the trial’s success, allowing the study to proceed smoothly and meet its objectives.
The Myonex Solution
Myonex leveraged its different drug sourcing capabilities to quickly source the number of required quantities of the drug, in each dosage, to cover the clinical trial needs, from trial start to finish.
Supplemental sourcing filled every gap in the supply chain to overcome the scarcity challenge and meet the patient and sponsor needs, where a single sourcing pathway would have failed.
A versatile integration of multiple sourcing channels ensured priority access to the drug, enabling seamless availability despite global constraints.
Throughout the entire study, clinical distribution to US investigational sites was successfully orchestrated by Myonex’ experts.
The Results:
Seamless Risk Management: Through diversified sourcing channels, we ensured uninterrupted supply, delivering unmatched reliability and peace of mind for the sponsor.
Accelerated Access to High-Demand Medication: Despite challenges in sourcing this sought-after drug, treatments were delivered to sites ahead of schedule, surpassing expectations.
Faster Study Start-Up: With sufficient drug quantities promptly ready for shipment, the trial was launched earlier, accelerating critical timelines.
Boosted Patient Enrollment: The absence of anticipated supply shortages enabled a smoother and faster enrollment process, exceeding projected figures.
Optimized Clinical Trial Budget: By significantly reducing the enrollment period, the sponsor achieved notable cost savings, enhancing overall study expenditures.
Conclusion:
While safeguarding the requested amounts of commercial drugs, Myonex enabled the clinical trial to run smoothly. Finally, timelines exceeded the sponsor’s expectations, making things easier for investigational sites and contributing to an enhanced patient experience.
